The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Conjugate Vaccines-Global Market Insights and Sales Trends 2024
Synopsis
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global Conjugate Vaccines market size is expected to reach US$ 12920 million by 2029, growing at a CAGR of 3.7% from 2023 to 2029. The market is mainly driven by the significant applications of Conjugate Vaccines in various end use industries. The expanding demands from the Children and Adults, are propelling Conjugate Vaccines market. Monovalent Conjugate Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Multivalent Conjugate Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Conjugate Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Conjugate Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Conjugate Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Conjugate Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Conjugate Vaccines covered in this report include Novartis, Neuron Biotech, Serum Institute of India, Pfizer, Sanofi Pasteur, Bharat Biotech, Biological, GlaxoSmithKline and Merck, etc.
The global Conjugate Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
Global Conjugate Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Conjugate Vaccines market, Segment by Type:
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
Global Conjugate Vaccines market, by Application
Children
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Conjugate Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Conjugate Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global Conjugate Vaccines market size is expected to reach US$ 12920 million by 2029, growing at a CAGR of 3.7% from 2023 to 2029. The market is mainly driven by the significant applications of Conjugate Vaccines in various end use industries. The expanding demands from the Children and Adults, are propelling Conjugate Vaccines market. Monovalent Conjugate Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Multivalent Conjugate Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Conjugate Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Conjugate Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Conjugate Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Conjugate Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Conjugate Vaccines covered in this report include Novartis, Neuron Biotech, Serum Institute of India, Pfizer, Sanofi Pasteur, Bharat Biotech, Biological, GlaxoSmithKline and Merck, etc.
The global Conjugate Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
Global Conjugate Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Conjugate Vaccines market, Segment by Type:
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
Global Conjugate Vaccines market, by Application
Children
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Conjugate Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Conjugate Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Conjugate Vaccines Market Overview
1.1 Conjugate Vaccines Product Overview
1.2 Conjugate Vaccines Market Segment by Type
1.2.1 Monovalent Conjugate Vaccines
1.2.2 Multivalent Conjugate Vaccines
1.3 Global Conjugate Vaccines Market Size by Type
1.3.1 Global Conjugate Vaccines Market Size Overview by Type (2018-2029)
1.3.2 Global Conjugate Vaccines Historic Market Size Review by Type (2018-2023)
1.3.3 Global Conjugate Vaccines Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Conjugate Vaccines Sales Breakdown by Type (2018-2023)
1.4.2 Europe Conjugate Vaccines Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Conjugate Vaccines Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Conjugate Vaccines Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Conjugate Vaccines Sales Breakdown by Type (2018-2023)
2 Global Conjugate Vaccines Market Competition by Company
2.1 Global Top Players by Conjugate Vaccines Sales (2018-2023)
2.2 Global Top Players by Conjugate Vaccines Revenue (2018-2023)
2.3 Global Top Players by Conjugate Vaccines Price (2018-2023)
2.4 Global Top Manufacturers Conjugate Vaccines Manufacturing Base Distribution, Sales Area, Product Type
2.5 Conjugate Vaccines Market Competitive Situation and Trends
2.5.1 Conjugate Vaccines Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Conjugate Vaccines Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Conjugate Vaccines as of 2022)
2.7 Date of Key Manufacturers Enter into Conjugate Vaccines Market
2.8 Key Manufacturers Conjugate Vaccines Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Conjugate Vaccines Status and Outlook by Region
3.1 Global Conjugate Vaccines Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Conjugate Vaccines Historic Market Size by Region
3.2.1 Global Conjugate Vaccines Sales in Volume by Region (2018-2023)
3.2.2 Global Conjugate Vaccines Sales in Value by Region (2018-2023)
3.2.3 Global Conjugate Vaccines Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Conjugate Vaccines Forecasted Market Size by Region
3.3.1 Global Conjugate Vaccines Sales in Volume by Region (2024-2029)
3.3.2 Global Conjugate Vaccines Sales in Value by Region (2024-2029)
3.3.3 Global Conjugate Vaccines Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Conjugate Vaccines by Application
4.1 Conjugate Vaccines Market Segment by Application
4.1.1 Children
4.1.2 Adults
4.2 Global Conjugate Vaccines Market Size by Application
4.2.1 Global Conjugate Vaccines Market Size Overview by Application (2018-2029)
4.2.2 Global Conjugate Vaccines Historic Market Size Review by Application (2018-2023)
4.2.3 Global Conjugate Vaccines Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Conjugate Vaccines Sales Breakdown by Application (2018-2023)
4.3.2 Europe Conjugate Vaccines Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Conjugate Vaccines Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Conjugate Vaccines Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Conjugate Vaccines Sales Breakdown by Application (2018-2023)
5 North America Conjugate Vaccines by Country
5.1 North America Conjugate Vaccines Historic Market Size by Country
5.1.1 North America Conjugate Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Conjugate Vaccines Sales in Volume by Country (2018-2023)
5.1.3 North America Conjugate Vaccines Sales in Value by Country (2018-2023)
5.2 North America Conjugate Vaccines Forecasted Market Size by Country
5.2.1 North America Conjugate Vaccines Sales in Volume by Country (2024-2029)
5.2.2 North America Conjugate Vaccines Sales in Value by Country (2024-2029)
6 Europe Conjugate Vaccines by Country
6.1 Europe Conjugate Vaccines Historic Market Size by Country
6.1.1 Europe Conjugate Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Conjugate Vaccines Sales in Volume by Country (2018-2023)
6.1.3 Europe Conjugate Vaccines Sales in Value by Country (2018-2023)
6.2 Europe Conjugate Vaccines Forecasted Market Size by Country
6.2.1 Europe Conjugate Vaccines Sales in Volume by Country (2024-2029)
6.2.2 Europe Conjugate Vaccines Sales in Value by Country (2024-2029)
7 Asia-Pacific Conjugate Vaccines by Region
7.1 Asia-Pacific Conjugate Vaccines Historic Market Size by Region
7.1.1 Asia-Pacific Conjugate Vaccines Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Conjugate Vaccines Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Conjugate Vaccines Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Conjugate Vaccines Forecasted Market Size by Region
7.2.1 Asia-Pacific Conjugate Vaccines Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Conjugate Vaccines Sales in Value by Region (2024-2029)
8 Latin America Conjugate Vaccines by Country
8.1 Latin America Conjugate Vaccines Historic Market Size by Country
8.1.1 Latin America Conjugate Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Conjugate Vaccines Sales in Volume by Country (2018-2023)
8.1.3 Latin America Conjugate Vaccines Sales in Value by Country (2018-2023)
8.2 Latin America Conjugate Vaccines Forecasted Market Size by Country
8.2.1 Latin America Conjugate Vaccines Sales in Volume by Country (2024-2029)
8.2.2 Latin America Conjugate Vaccines Sales in Value by Country (2024-2029)
9 Middle East and Africa Conjugate Vaccines by Country
9.1 Middle East and Africa Conjugate Vaccines Historic Market Size by Country
9.1.1 Middle East and Africa Conjugate Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Conjugate Vaccines Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Conjugate Vaccines Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Conjugate Vaccines Forecasted Market Size by Country
9.2.1 Middle East and Africa Conjugate Vaccines Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Conjugate Vaccines Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Conjugate Vaccines Products Offered
10.1.5 Novartis Recent Development
10.2 Neuron Biotech
10.2.1 Neuron Biotech Company Information
10.2.2 Neuron Biotech Introduction and Business Overview
10.2.3 Neuron Biotech Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Neuron Biotech Conjugate Vaccines Products Offered
10.2.5 Neuron Biotech Recent Development
10.3 Serum Institute of India
10.3.1 Serum Institute of India Company Information
10.3.2 Serum Institute of India Introduction and Business Overview
10.3.3 Serum Institute of India Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Serum Institute of India Conjugate Vaccines Products Offered
10.3.5 Serum Institute of India Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Pfizer Conjugate Vaccines Products Offered
10.4.5 Pfizer Recent Development
10.5 Sanofi Pasteur
10.5.1 Sanofi Pasteur Company Information
10.5.2 Sanofi Pasteur Introduction and Business Overview
10.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Pasteur Conjugate Vaccines Products Offered
10.5.5 Sanofi Pasteur Recent Development
10.6 Bharat Biotech
10.6.1 Bharat Biotech Company Information
10.6.2 Bharat Biotech Introduction and Business Overview
10.6.3 Bharat Biotech Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bharat Biotech Conjugate Vaccines Products Offered
10.6.5 Bharat Biotech Recent Development
10.7 Biological
10.7.1 Biological Company Information
10.7.2 Biological Introduction and Business Overview
10.7.3 Biological Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Biological Conjugate Vaccines Products Offered
10.7.5 Biological Recent Development
10.8 GlaxoSmithKline
10.8.1 GlaxoSmithKline Company Information
10.8.2 GlaxoSmithKline Introduction and Business Overview
10.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.8.4 GlaxoSmithKline Conjugate Vaccines Products Offered
10.8.5 GlaxoSmithKline Recent Development
10.9 Merck
10.9.1 Merck Company Information
10.9.2 Merck Introduction and Business Overview
10.9.3 Merck Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Merck Conjugate Vaccines Products Offered
10.9.5 Merck Recent Development
10.10 CSL
10.10.1 CSL Company Information
10.10.2 CSL Introduction and Business Overview
10.10.3 CSL Conjugate Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.10.4 CSL Conjugate Vaccines Products Offered
10.10.5 CSL Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Conjugate Vaccines Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Conjugate Vaccines Industrial Chain Analysis
11.4 Conjugate Vaccines Market Dynamics
11.4.1 Conjugate Vaccines Industry Trends
11.4.2 Conjugate Vaccines Market Drivers
11.4.3 Conjugate Vaccines Market Challenges
11.4.4 Conjugate Vaccines Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Conjugate Vaccines Distributors
12.3 Conjugate Vaccines Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
